296 results
8-K
SAVA
Cassava Sciences Inc
13 May 24
Submission of Matters to a Vote of Security Holders
4:30pm
as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified based upon the following
8-K
EX-99.1
SAVA
Cassava Sciences Inc
10 May 24
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
4:07pm
) – The DSMB is composed of independent clinical research experts who periodically review interim patient safety data. Routine, scheduled DSMB meetings
8-K
EX-99.1
5d6j1hut
28 Feb 24
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
9:22am
8-K
EX-99.1
lfrrkkr9o zk4
7 Feb 24
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
9:20am
424B2
8uo8f775e1 5eelaz7
3 Jan 24
Prospectus for primary offering
4:22pm
8-A12B
EX-4.1
848habk1dthy4viei
3 Jan 24
Registration of securities on exchange
4:18pm
8-K
EX-5.1
ss8faj8uqgfs4vp7qs
3 Jan 24
Entry into a Material Definitive Agreement
9:10am
8-K
EX-4.1
dv5831bb1oehk30puzz
3 Jan 24
Entry into a Material Definitive Agreement
9:10am
8-A12G
EX-4.1
9kr7bxpb6 q1nn
2 Jan 24
Registration of securities
9:10am
8-K
EX-99.2
pkd8rqxb
12 Dec 23
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
9:19am
8-K
EX-99.1
lash9kgqwa55nu88v
11 Dec 23
Cassava Sciences Appoints
4:18pm
8-K
bxh63uy
11 Dec 23
Cassava Sciences Appoints
4:18pm
8-K
EX-3.4
nbfv 7ympu
13 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:17pm